Sign in

You're signed outSign in or to get full access.

Sherry Coonse McCraw

Director at OneMedNet
Board

About Sherry Coonse McCraw

Independent Class III director at OneMedNet (ONMD), age 57, serving since October 2024 with a term expiring at the 2026 Annual Meeting. She brings 30 years of leadership at BMW Manufacturing Co., LLC across engineering, finance (including CFO/Vice President Finance), manufacturing operations (Vice President of Assembly Manufacturing), and Human Resources (current Vice President HR). She holds a B.S. in Textile Engineering from North Carolina State University and is designated by ONMD’s Board as an Audit Committee financial expert. Independence status: independent under Nasdaq and SEC rules. Attendance: no director attended fewer than 75% of Board and committee meetings in FY2024. Executive sessions: independent directors meet in executive session at each regularly scheduled Board meeting.

Past Roles

OrganizationRoleTenureCommittees/Impact
BMW Manufacturing Co., LLCTesting and Finish operations (start of career)1993 onward (multiple roles)Foundation in assembly, planning, engineering, technology steering
BMW Manufacturing Co., LLCProject Manager, Munich (structural planning for 2nd-gen BMW X5)2001Major platform planning responsibility
BMW Manufacturing Co., LLCPlanning Manager, Assembly & Technology Steering2004Assembly planning leadership
BMW Manufacturing Co., LLCManaged 1.2M sq ft plant expansion for X32007Large-scale capacity expansion
BMW Manufacturing Co., LLCLed $900M plant expansion (5th expansion)2011Largest single BMW investment; significant capex execution
BMW Manufacturing Co., LLCChief Financial Officer and Vice President Finance2013Senior financial leadership (CFO)
BMW Manufacturing Co., LLCVice President of Assembly ManufacturingMarch 2018 – April 2022Led both production halls
BMW Manufacturing Co., LLCVice President of Human ResourcesApril 2022 – presentCurrent executive role

External Roles

OrganizationRoleTenureCommittees/Impact
North Carolina Textile FoundationDirectorCurrentGovernance oversight for academic foundation

Board Governance

  • Committee assignments: Audit Committee member; Audit Committee held 4 meetings in 2024. Audit Committee Chair: Dr. Kenneth Alleyne. McCraw qualifies as an “audit committee financial expert” under SEC rules.
  • Other committees: Not listed as a member of Compensation or Nominating & Corporate Governance.
  • Independence: Board determined McCraw is independent under Nasdaq and SEC rules.
  • Attendance: No director attended fewer than 75% of Board and committee meetings in FY2024; Board held 2 meetings in 2024; Compensation Committee (1), Nominating & Corporate Governance (2), Audit (4).
  • Executive sessions: Independent directors meet in executive session during each regularly scheduled Board meeting.
  • Risk oversight: Audit Committee oversees financial reporting and cybersecurity; Compensation oversees compensation risk; Nominating & Governance manages independence/conflicts.

Fixed Compensation

ComponentFY2024 AmountNotes
Annual retainer (cash)$0 No cash retainer; policy reimburses reasonable out-of-pocket expenses
Committee membership fees$0 No committee fees disclosed
Committee chair fees$0 Not a chair; no chair fees disclosed
Meeting fees$0 No per-meeting fees disclosed
Equity – RSUs (policy)45,000 RSUs per full year Automatic annual grant under Director Compensation Policy adopted April 2024
FY2024 Equity – RSU grant fair value$6,579 Her FY2024 stock award grant-date fair value; likely prorated due to October appointment

Performance Compensation

Metric TypeDisclosed for Directors?Notes
Performance-based equity (PSUs)None disclosed Director compensation is time-based RSUs under policy; no disclosed performance metrics
Cash bonus tied to metricsNone disclosed No director cash bonuses disclosed

No director performance metrics (e.g., revenue growth, EBITDA, TSR) are disclosed for director compensation at ONMD; director equity is time-based RSUs under the policy.

Other Directorships & Interlocks

Company/OrganizationPublic Company?RolePotential Interlock/Conflict
North Carolina Textile FoundationNo (foundation)DirectorNo ONMD-related transactions disclosed

No public company directorships or interlocks with ONMD competitors/suppliers/customers were disclosed for McCraw.

Expertise & Qualifications

  • Deep cross-functional expertise: engineering, large-scale manufacturing expansions ($900M), finance (CFO), and human resources leadership at BMW.
  • Audit Committee financial expert designation by ONMD Board (SEC-defined).
  • Education: B.S. in Textile Engineering, North Carolina State University.

Equity Ownership

HolderShares Beneficially OwnedOwnership %Notes
Sherry Coonse McCraw11,342 <1% As of Oct 23, 2025; no breakdown of vested vs unvested disclosed
Hedging/Pledging PolicyProhibits hedging, short sales, and cashless collars; insider trading restrictions apply. Strengthens alignment; no pledging activity disclosed for McCraw

Insider Trades

ItemDate/PeriodDetail
Section 16(a) filings – timelinessFY2024Form 3 and Form 4 filings for McCraw (initial equity award upon Board appointment on Oct 1, 2024) were not filed on a timely basis, per ONMD disclosure.

Governance Assessment

  • Strengths

    • Independent director with designation as Audit Committee financial expert; sits on Audit Committee, which met 4 times in 2024.
    • Strong operational and financial leadership credentials from a global manufacturer (BMW), including major capex execution and CFO experience; relevant for audit oversight and internal controls.
    • Board-level policies: clawback adopted Nov 2024; prohibitions on hedging/short sales/options; independent directors meet in executive session.
    • Director pay structure is equity-heavy with no cash fees or meeting fees, aligning director incentives with long-term shareholder value.
  • Watch items / RED FLAGS

    • Late Section 16 filings (Form 3/4) noted for McCraw in FY2024; while administrative, repeated delays can signal governance process weaknesses.
    • Modest personal stake: 11,342 shares (<1%); alignment exists via annual RSUs but ownership is limited in absolute terms.
    • No disclosed public company boards or interlocks—reduces conflict risk, but also limits market-facing governance experience in public issuer contexts.
  • Conflicts and related-party exposure

    • No related-party transactions involving McCraw disclosed; Audit Committee reviews related-party transactions under policy.
  • Attendance and engagement

    • Board held 2 meetings in 2024; no director attended fewer than 75% of Board and committee meetings—no attendance red flags disclosed.
  • Committee structure and effectiveness

    • Audit chaired by Dr. Alleyne; McCraw is a member and designated financial expert—positive for financial oversight. Compensation and Nominating committees fully independent; clear charters and responsibilities.

Overall, McCraw enhances ONMD’s audit oversight through financial expert designation and extensive finance/operations background, with alignment supported by equity-based director pay and hedging prohibitions. Process discipline should be reinforced around timely Section 16 reporting to avoid governance optics issues.